NASDAQ$SLDB
Solid Biosciences Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Solid Biosciences reported positive interim efficacy and safety data from the ongoing IGNITE DMD clinical trial and the resumption of patient dosing in the 2E14 vg/kg cohort.
Solid Biosciences reported encouraging interim functional and biomarker data, and patient reported outcome measures (PROMs) from six patients after treatment in the ongoing IGNITE DMD Phase I/II clinical trial of its lead gene therapy candidate, SGT-001. The Company also announced that patient 7 in IGNITE DMD was safely dosed. The totality of data collected, and the re-initiation of dosing support the continued enrollment of patients into the IGNITE DMD study.
- Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints.
- Patient 7 safely dosed with SGT-001 experienced transient and manageable adverse events.
- Six patients previously dosed showed no new drug-related safety findings 17-37 months post dosing.
- Screening and enrolling of patients into IGNITE DMD continue.
Headline financials
Revenue & EPS history
Solid Biosciences · Revenue · Quarterly
$98.3M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-3.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+3.1%
Avg return
30 days after
50%
16 / 32 earnings
Positive
+19.0%
Q2 2019
Best reaction
-72.2%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.0% | +14.2% | +14.7% | |
| Q3 2025 | +7.4% | +15.3% | +46.8% | |
| Q1 2025 | +8.3% | +14.2% | +71.2% | |
| Q4 2024 | +5.3% | -9.6% | -50.5% | |
| Q3 2024 | -2.9% | +0.8% | -15.0% | |
| Q2 2024 | +16.6% | +23.9% | +7.8% | |
| Q1 2024 | -6.6% | -8.4% | -20.7% | |
| Q4 2023 | +7.7% | +17.2% | -9.0% | |
| Q3 2023 | -23.9% | -22.9% | +80.7% | |
| Q2 2023 | -1.1% | -1.1% | -12.9% | |
| Q1 2023 | +1.9% | +1.0% | +2.3% | |
| Q4 2022 | -2.6% | +5.0% | +28.6% | |
| Q3 2022 | +3.9% | +4.6% | -0.8% | |
| Q2 2022 | +6.5% | +15.3% | -10.8% | |
| Q1 2022 | -24.2% | -29.0% | -23.9% | |
| Q4 2021 | -7.0% | +34.0% | -0.9% | |
| Q3 2021 | +13.9% | +3.7% | -21.8% | |
| Q2 2021 | -3.0% | -7.1% | -1.1% | |
| Q1 2021 | -20.0% | -15.8% | -7.4% | |
| Q4 2020 | -32.5% | -38.9% | -44.3% | |
| Q3 2020 | -0.6% | -1.9% | +12.0% | |
| Q2 2020 | +0.0% | +8.0% | -13.6% | |
| Q1 2020 | -12.2% | -7.3% | +2.1% | |
| Q4 2019 | +18.5% | -4.5% | -22.0% | |
| Q3 2019 | -72.2% | -68.1% | -61.3% | |
| Q2 2019 | +19.0% | +79.9% | +96.1% | |
| Q1 2019 | -31.2% | -34.2% | -43.2% | |
| Q4 2018 | +0.3% | +4.7% | -9.9% | |
| Q3 2018 | +13.8% | +3.8% | -2.6% | |
| Q2 2018 | -1.2% | -1.1% | +2.5% | |
| Q1 2018 | +11.6% | +15.2% | +19.6% | |
| Q4 2017 | +1.9% | +12.7% | +86.2% | |
| Q3 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro